Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients.
DXG ([2R-cis]-2-amino-1,9-dihydro-9-[2-[hydroxymethyl]-1,3-dioxolan-4-yl]-6H-purin-6-one) and its prodrug DAPD ([2R-cis]-4-[2,6-diamino-9H-purin-9-yl]-1,3-dioxolane-2-methanol; amdoxovir) are novel 2',3'-dideoxynucleosides (ddNs) displaying activity against human immunodeficiency virus type 1 (HIV-1). In this paper, we describe the development of an enzymatic assay for determining the intracellular active metabolite of DXG and DAPD, DXG triphosphate (DXGTP), in peripheral blood mononuclear cells (PBMCs) from HIV-infected patients. The assay involves inhibition of HIV reverse transcriptase (RT), which normally incorporates radiolabeled deoxynucleoside triphosphates (dNTPs) into a synthetic template primer. DXGTP (0.6 pmol) inhibited control product formation with or without a preincubation step. Inhibition was greatest when the template primer was most diluted. DAPDTP inhibited control product formation only at very high levels (50 pmol) and when a preincubation procedure was used. However, reduced template primer stability in assays using preincubation steps, coupled with potential interference by DAPDTP, led to the current assay method for DXGTP being performed without preincubation. Standard DXGTP inhibition curves were constructed. The presence of PBMC extracts or endogenous dGTP did not interfere with the DXGTP assay. Intracellular DXGTP and dGTP concentrations were determined in PBMCs from HIV-infected patients receiving oral DAPD (500 mg b.i.d.). Peak concentrations of DXGTP were obtained 8 h after dosing and were measurable through 48 h postdose. Levels of endogenous dGTP were also determined over 48 h. No direct relationship was observed between concentrations of DXGTP and dGTP. Quantification of DXGTP concentrations in PBMCs from patients receiving a clinically relevant dose of DAPD is possible with this enzymatic assay.
Kewn
Stephen
S
Department of Pharmacology & Therapeutics, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, United Kingdom. Kewny@liverpool.ac.uk
Wang
Laurene H
LH
Hoggard
Patrick G
PG
Rousseau
Franck
F
Hart
Robert
R
MacNeela
John P
JP
Khoo
Saye H
SH
Back
David J
DJ
D004148:Dioxolanes / Q000097:blood* / Q000494:pharmacology; D006151:Guanosine / Q000031:analogs & derivatives* / Q000097:blood* / Q000494:pharmacology; D015658:HIV Infections / Q000097:blood* / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D011684:Purine Nucleosides / Q000097:blood* / Q000494:pharmacology
D004148:Dioxolanes; D011684:Purine Nucleosides; D006151:Guanosine; C063536:2-amino-1,9-dihydro-9-(2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl)-6H-purin-6-one; C098393:amdoxovir